Covid-19 Treatment Guide – Updated Protocol and Algorithm

We share updates on treatment as of October 2021 for Covid-19, the disease caused by the novel coronavirus scientifically named SARS-CoV-2.
The guide below is from UCHealth (University of Colorado Health), a nonprofit health system based in Colorado. It includes hospitals and facilities in Colorado and affiliated hospitals in Wyoming and Nebraska, and is among the USA's leading health authorities.
Treatment for Covid-19 patients can be considered in 3 categories, and recommended treatments differ between groups. The patient groups are:
- Outpatient prevention / post-exposure prophylaxis
- Outpatient treatment
- Inpatient treatment



Types of Medicines Used in Covid-19 Treatment, Indications and Drug Information
SARS-CoV-2 Monoclonal Antibodies
Covid-19 monoclonal antibodies (mAbs) are neutralizing antibodies produced in a laboratory against the SARS-CoV-2 spike protein. Among currently available mAbs, Casirivimab/Imdevimab is UCHealth's first-choice agent. mAbs continue to retain activity against variants currently circulating widely worldwide, including Alpha, Beta, Gamma and Delta. Other mAbs unavailable at UCHealth are Sotrovimab and the Bamlanivimab/Etesevimab combination. While Sotrovimab remains active against common variants, Bamlanivimab monotherapy is no longer recommended because it has lost activity against variants.
mAbs are primarily used in patient groups classified as “Outpatient Prevention” or “Outpatient Treatment.” In the prevention group, they are administered for prophylaxis (preventing disease after exposure to the virus), but may also be used for inpatient treatment in certain circumstances. Early use of mAbs covered by the FDA (US Food and Drug Administration Emergency Use Authorization (EUA) for prophylaxis may shorten symptom duration and prevent hospitalization and Covid-19-related deaths.
Who Can and Cannot Receive mAb Treatment?
For outpatient treatment in people aged 12 and over with a body weight of 40 kg or more, the criteria for administering mAb therapy are:
- Confirmed SARS-CoV-2 infection (positive PCR or antigen test)
- Mild and/or moderate symptoms for less than 10 days
- No oxygen requirement, but a high risk of severe disease*
However, they may exceptionally be used in people hospitalized for Covid-19 with a new oxygen requirement or an increase in oxygen flow rate from baseline (SpO2 < 90%). mAb treatment may also be considered if people were hospitalized for another reason (not Covid-19), are known to be negative, or are presumed to have an impaired humoral immune response.
In addition, if mAb treatment is to be given for prophylaxis, the person is expected to have been exposed to someone carrying SARS-CoV-2 at a distance of 6 steps or less for 15min or longer, or to have a high likelihood of infection following a positive case reported in the same institutional setting. Treatment criteria in these people are either a high risk of severe disease*, or incomplete or no vaccination, or an adequate immune response not being expected despite vaccination (for reasons such as immunosuppressive medication).
In addition, patients receiving passive antibody treatment (mAbs or plasma from recovered people) are recommended to postpone Covid-19 vaccination for 90 days to avoid possible interference with the vaccine-induced immune response.
*Note: The FDA has granted Emergency Use Authorization (EUA) for mAbs because some people are at high risk of severe disease. Conditions for inclusion in this risk group are:
- Age 65 and over
- Obesity or overweight (Body Mass Index (BMI) 25kg/m2)
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or treatment, including HIV infection
- Cardiovascular disease or hypertension, including congenital heart disease and cerebrovascular disease
- Chronic lung disease (such as COPD, asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension, or current or previous smoking)
- Sickle cell disease
- Neurodevelopmental disorders, including cerebral palsy, or genetic or metabolic syndromes or serious congenital abnormalities
- Dependence on medical devices such as a tracheostomy, gastrostomy or positive-pressure ventilation
- Other medical conditions or factors placing a patient at high risk of severe disease (for example, race or ethnicity, disability, substance use, etc.)
Prioritization Among Patients
When circumstances require prioritization for mAb therapy, the NIH (National Institutes of Health) Covid-19 Treatment Guidelines Panel states that Covid-19 treatment should take priority over prophylaxis.
In addition, people at high risk of severe disease who are incompletely or unvaccinated, or are not expected to develop an adequate immune response despite vaccination (immunocompromised), should be prioritized over vaccinated people expected to have adequate immunity.
Remdesivir (Veklury; RDV)
Remdesivir, a tier 2 restricted antimicrobial at UCHelath, is FDA-approved for adult and pediatric Covid-19 cases requiring hospitalization. A dose starting at 200mg on the first day and decreasing to 100mg on days 2 – 5 is recommended. It is used for 5 days, or until discharge if hospitalization lasts less than 5 days.
Who Can and Cannot Use Remdesivir?
Criteria for use in inpatients aged 12 and over with a body weight of 40 kg or more are:
- Confirmed SARS-CoV-2 infection (positive PCR or antigen test)
- Symptoms for less than 14 days (this period may be shorter for a transplant patient or someone with a suppressed immune system)
- Hypoxia requiring oxygen;
- Based on current evidence, patients initially requiring high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation and/or ECMO (Extracorporeal Membrane Oxygenation) are unlikely to benefit from RDV.
- Patients may continue RDV if they progress to mechanical ventilation or ECMO.
- ALT < 10x ULN (ALT, Alanine Aminotransferase; ULN, upper limit of normal)
Patients' LFTs (Liver Function Tests) should be monitored daily. If ALT > 10x ULN, it should be continued. Kidney failure is also not a contraindication (a situation in which a drug should not be used) for RDV. Only the RDV prescribing information recommends avoiding use in patients with CrCl (creatinine clearance from blood) <30mL/min because of the potential for accumulation of cyclodextrin and RDV leading to worsening kidney failure. However, given the small amount of cyclodextrin in RDV and the short treatment duration, adverse effects are unlikely, and several retrospective studies found no increased risk of serious or nonserious effects (including renal or hepatotoxicity).
Dexamethasone
Dexamethasone is indicated (meaning treatment with dexamethasone is necessary) in Covid-19 patients requiring oxygen, including mechanical ventilation or ECMO. However, it is not recommended if patients do not need oxygen. In pregnancy, consultation with Maternal Fetal Medicine regarding steroid use is recommended.
Deksametazom is administered orally or IV at 6mg daily for 10 days or until discharge. However, if hospitalization will be shorter than 10 days and the patient's oxygen requirement is still increasing, completing 5-7 days of hospitalization is recommended.
In addition, alternative medicines that can be used in the absence of deksametazom are Prednisone (40mg daily), Methylprednisolone (32mg daily) and hydrocortisone (160m daily).
Tocillizumab (Actemra)
Tocillizumab, an IL-6 receptor antagonist used in rheumatoid arthritis and CAR-T-related treatment of cytokine release syndrome, previously had conflicting results in Covid-19 treatment. However, two recent studies suggest a mortality benefit when used with corticosteroids in a selected group of hospitalized patients with rapid respiratory decompensation (impaired respiratory balance).
Who Can and Cannot Use Tocillizumab?
It should be considered as an addition to steroids in people hospitalized for 3 days or less who are transferred to intensive care (within 24 hours) with high oxygen needs, or who have not yet been transferred but have rapidly increasing oxygen requirements needing HFNC (humidified high-flow nasal oxygen) or NIV (Non-Invasive Ventilation) and substantially elevated inflammatory signs (CRP ≥ 75mg/L). Nevertheless, assessment of the response to corticosteroids over a period such as 48 hours is recommended before deciding on tocilizumab.
The development or recurrence of latent infection should be monitored. Testing is recommended according to risk factors. Prophylactic ivermectin treatment is also recommended in patients from areas endemic for Strongiloides.
However, tocilizumab has not yet been shown to benefit patients requiring mechanical ventilation (unless intubated for less than 24 hours).
In addition, tocillizumab should be avoided in severely immunocompromised people, those with suspected but unconfirmed other infection, AST/ALT >5x ULN (AST, Aspartate Aminotransferase), ANC < 500 and platelets <50K (ANC, Absolute Neutrophil Count), those at risk regarding GI (glycemic index, the rate at which carbohydrates raise blood sugar), and in pregnancy.
Baricitinib (Olumiant)
Some data for baricitinib, used as a JAK (Janus Kinase) inhibitor in rheumatoid arthritis, show that giving it with RDV helps shorten recovery in patients needing oxygen. When given with dexamethasone or dexamethasone and RDV in patients requiring oxygen or high-flow oxygen / NIV (excluding mechanical ventilation), it reduced 28-day all-cause mortality. Baricitinib was also most beneficial among patients initially requiring HFNC/NIV.
Based on this, the NIH Guideline recommends one of the following for inpatients using high-flow oxygen or NIV whose clinical course is being observed or who have signs of increasing inflammation:
- Dexamethasone alone with Baricitinib OR tocilizumab
- Dexamethasone and remdesivir with Baricitinib OR tocilizumab
- In the rare circumstances where corticosteroids cannot be used, baricitinib + remdesivir for hospitalized, nonintubated patients requiring oxygen
However, additional treatment will be needed in Covid-19 patients hospitalized for less than 72 hours who require HNFC or NIV, have worsening respiratory function despite dexamethasone, and persistently elevated C-reactive protein.
Who Can and Cannot Use Baricitinib?
Assessment of the response to corticosteroids over a period such as 48 hours is recommended before deciding on baricitinib. It has not been evaluated in patients requiring ventilation initially, but treatment may nevertheless continue in those who progress to mechanical ventilation after starting baricitinib. Drug interactions should be reviewed, CBC (Complete Blood Count) and pulse monitored daily, LFT monitored weekly, and patients monitored for latent or potentially recurrent infection.
However, baricitinab should be avoided in people with EGFR < 15mL/min/1.73m2, ALC < 200cells/µL, ANC < 500cells/µL, hemoglobin < 8g/dL, known active tuberculosis, and in pregnancy. Treatment may be started or continued when ALC rises to 200 and ANC to 500.
Convalescent Plasma
Convalescent plasma (CCP), containing plasma from people who have recovered from Covid-19 and neutralizing antibodies against SARS-CoV-2, initially received Emergency Use Authorization for Covid-19 treatment, but ongoing studies have produced conflicting results. Recent studies show no clinical benefit in hospitalized patients, including with high-titer plasma.
CCP is therefore not recommended in hospitalized or nonhospitalized patients. It is recommended only in the context of a clinical study. Outside this, if it is still desired in circumstances such as a patient benefiting from passive immunity but being unsuitable for mAb therapy, it should be used via empty blood.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.